Future Events
full calendarEURL ECVAM
ESTIV Applied Training Course shortlisted for LUSH Prize
ESTIV is proud to announce that its training programme in NAMs (New approach Methodologies), the ESTIV Applied Training course, has been shortlisted for the 2022 LUSH prize.
Guidance and standards for increasing regulatory confidence in in vitro and PBK models
Please join us on Thursday, July 28, 2022 for our next joint ESTIV-ASCCT webinar: Guidance and standards for increasing regulatory confidence in in vitro and PBK models…
NURA Sessions – DyNAMic Discussions: The Future is Already Here
Please join the Physicians Committee for Responsible Medicine’s New Approach Methodologies (NAMs) Use for Regulatory Applications (NURA) Friday, June 24 at 10:00-11:30 am EDT …
ASCCT-ESTIV special webinar for Ukraine: Science for Policy, Policy for Science – June 27, 2022
ESTIV and ASCCT joined forces and organise a special webinar to support Ukraine….
Advancing In Vitro Models for Genotoxicity and Carcinogenicity – May 16, 2022
Please join us on Monday May 16 at 17:00 for our next joint ESTIV-ASCCT webinar: Advancing In Vitro Models for Genotoxicity and Carcinogenicity
featuring Anouck Thienpont, PhD Student, VUB Belgium and Dr. Silvia Scaglione, React4life (ESTIV Corporate member) and the winner of the GammaDonna award 2021.
JRC Published the 2021 report on Non-animal Methods in Science and Regulation
The 2021 edition of the EURL ECVAM status report “Non-animal methods in science and regulation” has just been published. The report covers our activities on alternatives to animal testing from research over validation and international adoption to education including international collaboration networks.
ESTIV Training course newsletter – all you need to know about the course and more…
Thinking about updating your knowledge on NAMs? This is a meeting to attend….
Development and evaluation of NAMs for new endpoints: Developmental neurotoxicity and respiratory sensitization – April 14, 2022
Time to register for the April ASCCT-ESTIV webinar: Development and evaluation of NAMs for new endpoints: Developmental neurotoxicity and respiratory sensitization, featuring Sabina Burla, Luxembourg Institute of Science and Technology (LIST), and Kelly Carstens, PhD, US EPA ORISE.